Latest revenue
—
as of 2025-12-31
Latest net income
$-101.7M
as of 2025-12-31
Net margin
—
as of 2025-12-31
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Pharmaceutical Preparations (528 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 6, 2026.
Community sentiment
Where do you think ALXO is heading?
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $205.9M
- Enterprise value
- $187.3M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- 1.36×
- Dividend yield
- 0.0%
- 52-wk high
- $2.66
- 52-wk low
- $0.40
- Beta
- —
- Shares out
- 134.6M
5-year trend
What this company does
Item 1. Business. BUSINESS Overview We are a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives. Our clinical pipeline includes two clinical-stage product candidates, the CD47 blocker evorpacept and an epidermal growth factor receptor (EGFR)-targeted antibody drug candidate (ADC) ALX2004. Our lead product candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built for patients whose cancer over-expresses CD47. Evorpacept is currently being evaluated in combination with trastuzumab and chemotherapy in patients with metastatic…
AI summary unavailable — showing raw filing excerpt
Generated from ALXO's filing dated 2026-03-09
Key risks
Item 1A. Risk Factors. RISK FACTORS Investing in our common stock involves a high degree of risk. You should carefully consider the risks described below, together with the other information contained elsewhere in this Annual Report on Form 10-K, including our consolidated financial statements and the related notes, Part II, Item 7. “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and our other filings with the Securities and Exchange Commission, or SEC, before deciding whether to invest in our common stock. The occurrence of any of the events or developments described below could harm our business, financial condition, results of operations and…
AI summary unavailable — showing raw filing excerpt
Generated from ALXO's filing dated 2026-03-09
Profitability
Return on equity
-89.5%
24.6%Return on assets
-172.2%
88.7%Leverage
Debt / equity
-0.48×
259.8%Long-term debt / equity
0.04×
52.1%Debt / assets
-92.4%
499.9%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | — | — | $-17.9M | +41.7% | — |
Q4 2025 2025-12-31 | — | — | $-22.8M | +21.7% | — |
Q3 2025 2025-09-30 | — | — | $-22.1M | +27.9% | — |
Q2 2025 2025-06-30 | — | — | $-25.9M | +34.1% | — |
Q1 2025 2025-03-31 | — | — | $-30.8M | +13.6% | — |
Q4 2024 2024-12-31 | — | — | $-29.2M | — | — |
Q3 2024 2024-09-30 | — | — | $-30.7M | +39.8% | — |
Q2 2024 2024-06-30 | — | — | $-39.4M | -15.3% | — |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Pharmaceutical Preparations · SIC 2834
Your notes
Keep private notes on ALXO — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$5.2M
Insider selling
$37.8K
Net activity
+$5.1M
Distinct insiders
4
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns ALXO
Institutional value
$14.4M
Total shares held
8.3M
Distinct holders
28
-29 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 4.2M | $8.4M | — | New |
| 2 | Ensign Peak Advisors, Inc | 950.5K | $1.9M | — | New |
| 3 | UBS Group AG | 914.8K | $1.8M | +48.8K (+5.6%) | Added |
| 4 | BlackRock, Inc. | 447.8K | $897.8K | -2.6K (-0.6%) | Trimmed |
| 5 | VANGUARD FIDUCIARY TRUST CO | 294.5K | $590.4K | — | New |
| 6 | VANGUARD PORTFOLIO MANAGEMENT LLC | 97.9K | $196.3K | — | New |
| 7 | JANE STREET GROUP, LLC | 95.1K | $190.7K | -90.9K (-48.9%) | Trimmed |
| 8 | WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | 38.0K | $74.9K | +5 (+0.0%) | Added |
| 9 | HC Advisors, LLC | 22.9K | $45.9K | -1.0K (-4.2%) | Trimmed |
| 10 | Callan Family Office, LLC | 22.4K | $45.0K | -5.9K (-20.8%) | Trimmed |
| 11 | NINE MASTS CAPITAL Ltd | 20.6K | $41.3K | +5.1K (+33.3%) | Added |
| 12 | JSF Financial, LLC | 17.5K | $35.1K | +0 (+0.0%) | No change |
| 13 | MONETA GROUP INVESTMENT ADVISORS LLC | 15.2K | $30.5K | +0 (+0.0%) | No change |
| 14 | Lido Advisors, LLC | 13.2K | $26.5K | +0 (+0.0%) | No change |
| 15 | Abel Hall, LLC | 12.6K | $25.3K | +0 (+0.0%) | No change |
| 16 | Invesco Ltd. | 11.0K | $22.0K | — | New |
| 17 | HSBC HOLDINGS PLC | 10.1K | $20.5K | -10.1K (-50.0%) | Trimmed |
| 18 | Vanguard Global Advisers, LLC | 10.0K | $20.0K | — | New |
| 19 | NISA INVESTMENT ADVISORS, LLC | 1.1K | $2.2K | +0 (+0.0%) | No change |
| 20 | ACADIAN ASSET MANAGEMENT LLC | 1.1M | $2.2K | -273.2K (-19.9%) | Trimmed |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once ALXO's latest filing finishes processing.
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.